Second generation liposomal cancer therapeutics: Transition from laboratory to clinic

  • Sen K
  • Mandal M
  • 86

    Readers

    Mendeley users who have this article in their library.
  • 36

    Citations

    Citations of this article.

Abstract

Recent innovations and developments in nanotechnology have revolutionized cancer therapeutics. Engineered nanomaterials are the current workhorses in the emerging field of cancer nano-therapeutics. Lipid vesicles bearing anti-tumor drugs have turned out to be a clinically feasible and promising nano-therapeutic approach to treat cancer. Efficient entrapment of therapeutics, biocompatibility, biodegradability, low systemic toxicity, low immunogenicity and ability to bypass multidrug resistance mechanisms has made liposomes a versatile drug/gene delivery system in cancer chemotherapy. The present review attempts to explore the recent key advances in liposomal research and the vast arsenal of liposomal formulations currently being utilized in treatment and diagnosis of cancer.© 2013 Elsevier B.V.

Author-supplied keywords

  • Cancer therapeutics
  • Drug delivery
  • Liposomes
  • Second generation

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Kacoli Sen

  • Mahitosh Mandal

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free